Within JITC's full catalog of published articles, a number of collections are available to provide readers with opportunities to view sets of papers following particular themes. The two newest collections that continue to receive new publications include the Immune Checkpoints Beyond PD-1 Review Series and the COVID-19 Collection.
The Journal for ImmunoTherapy of Cancer
is an open access journal that publishes high quality research, literature reviews, position papers and practice guidelines, and case studies on all components of cancer immunology and immunotherapy.
The Journal for ImmunoTherapy of Cancer (JITC) is the open access, peer reviewed journal that publishes on all aspects of tumor immunology and cancer immunotherapy, aiming to enrich communication and advance scientific understanding in this rapidly evolving field. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.
As a way to say thank you to the dedicated Society for Immunotherapy of Cancer (SITC) members who tirelessly work to advance the science and improve the lives of patients with cancer, SITC will provide members with a 50% discount on article processing charges for all member-authored 2021 publications.
EDITOR-IN-CHIEF
Pedro J. Romero, MD, University of Lausanne
Editorial Board
- Impact Factor
- 10.252
